TG Therapeutics to Host Q3 2024 Conference Call
TG Therapeutics, Inc. (NASDAQ: TGTX) has announced an upcoming conference call designed to discuss their financial results from the third quarter of 2024 and to offer insights into their business outlook for the remaining year. The call is scheduled for a Monday morning. Expect Michael S. Weiss, the Chairman and Chief Executive Officer, to lead the discussion, providing key information that could impact investors and stakeholders alike.
How to Join the Call
For those wishing to participate, you can join the call by dialing two specific numbers depending on your location: 1-877-407-8029 within the U.S. or 1-201-689-8029 for those calling from outside the U.S. Ensure to mention the Conference Title: TG Therapeutics Earnings Call to stay informed about the updates and financial statuses being shared. Additionally, a live webcast will be accessible via the Events page on the company's website, providing an alternative option for involvement. After the call, an audio recording will be available for replay, allowing followers to revisit the key topics discussed.
Anticipated Financial Announcements
Leading up to the conference call, TG Therapeutics will be issuing a press release to announce their financial results. This information will be crucial as stakeholders assess the company's performance in the competitive biopharmaceutical space.
About TG Therapeutics
TG Therapeutics is a biopharmaceutical company that is fully integrated and in the commercial stage. Their dedication is evident as they focus on developing and commercializing innovative treatments specifically for B-cell diseases. Their research pipeline features investigational medicines, showcasing their commitment to advancing healthcare solutions.
BRIUMVI® Approval
One of the shining stars of TG Therapeutics is their product BRIUMVI® (ublituximab-xiiy), which has received approval from the U.S. Food and Drug Administration (FDA). This medication is intended for the treatment of adult patients who are suffering from relapsing forms of multiple sclerosis, which includes several conditions such as clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Furthermore, they also attained approvals in Europe, demonstrating their international reach and commitment to maximum efficacy.
Staying Connected with TG Therapeutics
For more updates, interested parties can visit the TG Therapeutics website. By staying connected through their Investor & Media section, you can access essential information about their future endeavors. Follow them on X (formerly Twitter) and LinkedIn for real-time updates and insights into their corporate activities.
Frequently Asked Questions
What is the purpose of the upcoming conference call?
The conference call will outline TG Therapeutics' third-quarter financial results and provide a business outlook for the remainder of the year.
Who will be hosting the conference call?
Michael S. Weiss, the Chairman and CEO of TG Therapeutics, will host the call.
How can I access the live webcast of the conference call?
The live webcast can be accessed via the Events page of the TG Therapeutics website located in the Investors & Media section.
What notable product has TG Therapeutics received FDA approval for?
TG Therapeutics has received FDA approval for BRIUMVI® (ublituximab-xiiy), which is used to treat specific forms of multiple sclerosis.
How can I stay updated with TG Therapeutics' news?
You can follow TG Therapeutics on social media platforms like X and LinkedIn, as well as visit their website for the latest announcements and information.